PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

Trial Profile

PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Results (n=36) assessing preliminary safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
    • 03 Aug 2016 New trial record
    • 07 Jun 2016 Interim results (n=29) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top